Langland, a Publicis Health company, has announced that it has been chosen by the UK mental health charity, Mind, as its new strategic and creative partner of choice.

Working closely together as part of the collaboration, the two organisations are set to launch a new nationwide campaign during Mental Health Awareness Week in May.

The campaign will focus on encouraging people to speak up about their mental health, with the aim of prompting those who need it to seek the necessary support and advice. It will be the first overarching brand campaign to be launched by the mental health charity.

Sharing her thoughts on the partnership, Katie McMorran, managing partner, advertising at Langland.“We are thrilled to be working with Mind and supporting them with the launch of a national mental health campaign. From the moment we received the RFP, we were fighting to get in front of the team and share our ideas.”

She added: “Increasing mental health literacy, reducing the stigma associated with mental health issues and providing adequate support are central to our belief that there is no health, without mental health. Partnering with Mind is a fantastic opportunity to make a difference together.”

Around one in four people experience a mental health problem every year, while hundreds of thousands of people are unable to get the help that they need.
  
Langland will be tasked with providing leadership and strategy for the development and creative execution of the new multichannel campaign, with plans for the campaign to be broadcast over cinema, television commercials and social media in the hopes of encouraging people to seek support.

Mind’s associate director of external relations, Jennifer Walters, said: “We know that one in four adults and more than one in six young people experienced poor mental health for the first time during the pandemic. And that, for many already with mental health problems, this has got worse since the first national lockdown. We really want this campaign to support as many people as possible to recognise and prioritise their own mental health and to take that all-important step to seeking support and advice.”

The Policy Analysis leadership team (from left: Derek Weycker, PhD, Partner; Thomas Delea, MSIA, Partner; Chad Rose, Chief Operating Officer; Gerry Oster, PhD, Managing Partner

The addition of PAI now makes Fishawack one of the largest teams, with PAI’s group of more than 30 professionals joining Fishawack’s existing team of technical experts and strategy consultants.

The VEA team is also made up of the US-based market access consultancy Skysis and global market access consultancy PRMA Consulting, which joined FH in 2020 and 2021, respectively.

Fishawack created VEA to support its clients in responding more effectively to the rapidly evolving global market access environment. The agency has formed a comprehensive set of capabilities and services, furthering its ability to help clients effectively meet complex requirements.

Additionally, Fishawack clients will be able to benefit from its proprietary HEOR and market access digital platforms, developed to support biopharmaceutical and medical technology organisations in decision-making during clinical development.

PAI’s capabilities include HEOR strategy development, economic modelling, evidence-generation planning, real-world evidence and trial-based data analytics, health technology assessment and evidence synthesis. PAI also launched an innovative digital platform in 2018 – hēRo3 – that has streamlined HEOR modelling at many biopharmaceutical companies.

Gerry Oster, managing partner at PAI, will become Fishawack’s new global head of health economics, bringing more than 30 years of experience in HEOR to the team. Oster said: “When the FH and PAI leadership teams met for the first time, the synergies and fit were immediately apparent. It was clear that we shared not only core values as companies, but also a vision of how, together, we could bring significant value to our clients.”

Speaking on PAI’s capabilities, Jon Koch, CEO at Fishawack Health, said: “With their expertise, we are uniquely positioned to offer truly insightful strategic thinking and technical execution to meet payers’ evolving demands. These services are integral for helping our clients make critical decisions early in product development, mitigating some of the risks of bringing new molecules and indications to market.”